Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting

Phase 2

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Sponsor:

Allogene Therapeutics

Code:

NCT06500273

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemacabtagene ansegedleucel

ALLO-647

Fludarabine

Cyclophosphamide

Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Allogene Therapeutics on 2025-03-25.